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Abstract: 
 
Introduction 
The utility of Circumferential Resection Margin (CRM) status in predicting prognosis 
in oesophageal cancer is controversial, with different definitions used by the College 
of American Pathologists and the Royal College of Pathologists. We aimed to 
determine prognostic significance of CRM involvement and evaluate which system is 
the best predictor of prognosis.  
 
Methods 
A cohort of 390 patients who had potentially curative oesophagectomy (-+ 
neoadjuvant chemotherapy) were analysed. Associations between CRM involvement 
and patient outcome were assessed for the whole cohort, and for pre-specified 
subgroups of T3 tumours and those who received neo-adjuvant chemotherapy. 
Results 
CRM-involvement was associated with higher T and N stage, tumour differentiation, 
increased tumour length and both lymphovascular and perineural invasion. Overall 
Survival (OS) and Recurrence Free Survival (RFS) significantly worsened with CRM-
involvement (p=0.001, p<0.001). R1a (< 1mm but no macroscopic involvement) 
resulted in significantly improved OS (p=0.037) and RFS (P=0.026) compared to R1b 
(macroscopic involvement), but did not differ significantly from R0 (≥ 1mm).  The 
association between CRM-involvement and both OS and RFS remained significant 
regardless of whether neoadjuvant chemotherapy was given. However, CRM-
involvement was not a significant prognostic marker in T3 patients (p=0.148). 
Multivariable analysis found N stage, lymphovascular invasion, patient age and 
neoadjuvant chemotherapy to be significantly predictive of patient outcome. CRM-
involvement was not a significant independent prognostic marker. 
 
Conclusions 
CRM-involvement was not found to be independently predictive of prognosis, after 
accounting for other prognostic markers. As such, CRM should not be considered a 
major prognostic factor in patients with oesophageal cancer.  [250] 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
3 
 
 
Keywords: ‘Oesophageal cancer’, ‘Oesophagectomy’, ‘Circumferential Resection 
Margin’, ‘Survival’, ‘Recurrence’. 
 
Word Count (Main Text):  
 
Funding: This study was completed with funding from the Queen Elizabeth Hospital 
Birmingham Charity (Upper Gastrointestinal Fund) and the Upper GI Blues Charity, 
Sandwell.  
 
Acknowledgements: We would like to thank all of the Consultant Upper GI Surgeons 
and the Multi-Disciplinary Team from the University Hospitals of Birmingham NHS 
Foundation Trust for allowing their patients to be included in this study. Finally, our 
gratitude goes to the patient support group charities for supporting this project. 
 
Disclosures: Lauren Quinn, Alexander Hollis, James Hodson, Mona Elshafie, Mike 
Hallissey, John Whiting and Ewen Griffiths have no conflicts of interest to declare. 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
4 
 
Introduction  
 
Oesophageal cancer is the sixth most common cancer in the developed world(1) and 
incidence continues to rise, due to rising rates of  obesity, reflux disease and 
Barrett’s oesophagus(2). Although oesophagectomy is performed with curative 
intent, disease recurrence is common within two years of surgery(3) and survival 
rates remain poor (3–5).    
 
Resection margin status is an important prognostic finding and involvement of the 
proximal and/or distal resection margins is associated with a significantly worse 
prognosis in terms of recurrence and survival(6). However, the prognostic 
significance of circumferential resection margin (CRM) involvement in oesophageal 
cancer remains unclear. Interest in CRM stems from the overwhelming significance 
of CRM as a negative prognostic marker in rectal cancer studies(7). Numerous 
studies have investigated CRM in oesophageal cancer but have elicited conflicting 
results, with some showing it is a significant prognostic factor(8–15) whereas others 
show that it does not add valuable prognostic information(16,17). 
 
CRM status has been defined differently by the College of American Pathologists (18) 
and Royal College of Pathologists (19). The College of American Pathologists 
classifies CRM into clear (R0) and involved (R1) if the tumour lies directly at the 
margin(18), whereas British Royal College of Pathologists guidelines(19) class 
tumours within 1mm as involved (R1).   In our unit, pathologists have used a hybrid 
classification system for CRM status.  This is defined as R0 if the CRM is uninvolved at 
≥1mm, R1a for CRM < 1mm but not grossly involved and R1b if the CRM is directly 
involved at 0mm. Although some studies(20–26) have attempted to define which 
classification system is best, this is currently an understudied area, especially in the 
era of neoadjuvant therapy for oesophageal cancer.  It is also unclear whether 
operative technique, including the use of minimally invasive oesophagectomy affects 
the rate of CRM involvement.  
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The aim of this study was to 1) assess the prognostic significance of CRM 
involvement in a modern cohort of patients, 2) compare and contrast the College of 
American Pathologists and Royal College of Pathologists definitions and assess our 
hybrid classification in order to identify an optimal cut-off for CRM involvement and 
finally 3) consider the effect of neoadjuvant chemotherapy / use of minimally 
invasive surgery on the significance of CRM as a prognostic marker. 
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Methods 
A retrospective analysis of consecutive patients was performed on a prospectively 
collected departmental database from January 2006 to July 2016. Patients who 
underwent a non-curative resection on final pathology due to either proximal or 
distal resection margin involvement (n=11) or due to unsuspected metastatic disease 
(n=11) were excluded from the study. The circumferential resection margin status of 
these excluded patients, were R0 in 8 (36%), R1a in 4 (18%) and R1b in 10 (45%). 
After these exclusions, a total of n=390 were available for analysis. This dataset 
included patient demographics, staging investigations, operative details, oncological 
treatment, histopathology reports and long-term follow-up with recurrence and 
survival reported. All patients had surgical resection performed at the Queen 
Elizabeth Hospital, Birmingham.   Our standard catchment area included patients 
from other sites across the West Midlands Region, including Manor Hospital, Walsall; 
Russells Hall Hospital, Dudley and City Hospitals, West Birmingham.  Some patients 
who were managed at our tertiary centre came from further afield.   'This study did 
not require ethical approval as it was a retrospective review of database 
 
When follow-up data were missing, clinical records were analysed in the respective 
hospitals. Inclusion criteria consisted of patients with oesophageal cancer who 
received oesophagectomy with curative intent. The majority of patients received 
neoadjuvant chemotherapy as per recent randomized controlled trial 
evidence(27,28).      
 
During the time frame of the study, oesophagectomy procedures were performed by 
specialist Upper Gastrointestinal Consultant Surgeons (total n=10) who used similar 
techniques.  Oesophagectomies were classified as: (1) open 2 or 3 stage procedures 
involving open abdominal incisions with open right thoracotomy; (2) laparoscopic 
abdominal gastric mobilization with an open right thoracotomy (hybrid 
oesophagectomy) plus or minus cervical incision; or (3) minimally invasive 
oesophaghectomy (MIO) with laparoscopic and thoracoscopic oesophageal 
mobilization with either intra-thoracic or cervical anastomosis. The decision 
regarding operative method was at the discretion of the Consultant Surgeon 
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involved. Operative methods evolved over the time period of the study. The first 
laparoscopic gastric mobilization was performed in the unit in 2006 and fully 
minimally invasive procedures were introduced in 2008.   
 
 
Histopathological assessment 
After receipt of the oesophagogastrectomy specimen in the laboratory, the CRM was 
inked and allowed to dry. Subsequently, the specimens were opened longitudinally 
from proximal to distal, extending this incision distally along the greater curve of the 
stomach. The resections were pinned on corkboard then left to fix in formalin for at 
least twenty four hours. The macroscopic features were then recorded, including 
tumour dimensions measured to the closest 1mm. The tumours were thinly (3-5mm) 
sliced transversely from 2cm above to 2cm below, with areas showing tumour 
closest to the inked circumferential margin sampled for microscopy (Figure 1).  
Involvement of a surgical resection margin was classified as R0 if the CRM was 
uninvolved (≥1mm), R1a if the CRM involved < 1mm but was not grossly involved, or 
R1b if the CRM was directly involved (0mm)(18,19). At least four blocks of tumour 
were examined histologically as were all resection margins, representative areas of 
oesophagus and stomach, any additional macroscopic abnormalities and all lymph 
nodes identified.   
 
The Siewert classification system was used to classify junctional tumours(29). The 7
th
 
edition of the TNM system was used(30). Mandard grading was used to classify 
response to chemotherapy(31).    
 
Statistical Methods 
 
Initially, a range of patient, disease and treatment related factors were compared 
between the three CRM groups based on the hybrid classification. Where a 
significant difference was detected, post-hoc pairwise comparisons were performed 
between R1a and the other two groups. Continuous variables were assessed for 
normality, prior to analysis. Those that were found to be normally distributed were 
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reported as mean ± standard deviation (SD), with one-way ANOVA used to compare 
across groups, followed by Dunnett’s post-hoc tests. Non-normal and ordinal 
variables were reported as medians and interquartile ranges (IQRs), with 
comparisons across groups performed using Kruskal-Wallis tests followed by 
pairwise Dunn’s tests. Nominal variables were compared using Fisher’s exact test, 
followed by Bonferroni-corrected pairwise Fisher’s exact tests, where significance 
was observed. In cases where Fisher’s exact test was incalculable, due to a large 
number of groups, the Chi
2
 test was used instead. Survival outcomes were assessed 
using Kaplan-Meier curves, with univariable Cox regression models used to produce 
hazard ratios (HRs) and 95% confidence intervals (95% CIs). Follow up was started at 
the point of surgery, with all subsequent deaths (including inpatient mortality) 
treated as outcomes. 
 
CRM was then dichotomised based on the American College of Pathologists and 
Royal College of Pathologists guidelines(18,19). Univariable Cox regression models 
were produced for each definition of CRM for both the cohort as a whole, and within 
pre-defined patient subgroups. Multivariable Cox regression models were then 
produced, to consider the association between CRM and patient outcomes, after 
accounting for other potentially confounding factors. A backwards stepwise 
approach was used to select independent predictors of patient outcome. The CRM 
variables were then individually added to the resulting model. 
 
All analyses were performed using IBM SPSS 22 (IBM Corp. Armonk, NY). Missing 
data were excluded on a per-analysis basis, and p<0.05 was deemed to be indicative 
of statistical significance throughout. 
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Results  
 
Study Group 
 
A total of 390 patients who underwent oesophagectomy with curative intent for 
oesophageal cancer were included in this study. The mean age of the cohort was 
67.3 ± 9.2 years (range 23-89 years), and 79% (N=308) were male. The majority of 
patients had adenocarcinoma (n=308, 79%), and tumours were principally located in 
the lower 1/3 of the oesophagus or Siewert type 1 (n=283, 73%) . Surgery was 
generally by hybrid (n=164, 42%), open (n=93, 24%) or minimally invasive (n=86, 
22%) oesophagectomy, and the majority of patients received neoadjuvant 
chemotherapy (n=298, 77%). Post-operative mortality rates were 3.9% and 6.9% at 
30 and 90 days, respectively. 
 
CRM Involvement in relation to other histopathological factors and patient 
outcomes 
 
In our cohort, 66% of patients had an R status of R0, with the remainder divided 
between R1a (18%) and R1b (16%). CRM involvement was only identified in patients 
with T3 or T4 staging. Associations between resection margins and a range of factors 
are reported in Tables 1a and 1b. Higher R status was found to be associated with 
significantly poorer differentiation (p<0.001), higher T stage (p<0.001) and N- stage 
(p<0.001), and higher rates of peri-neural (p<0.001) and lymphovascular invasion 
(p<0.001). In addition, those with higher R status had significantly greater numbers 
of lymph nodes (p=0.016), of which more were positive (p<0.001). Higher Rstatus 
also associated with greater tumour length (p=0.014) and reduced responsiveness to 
chemotherapy, as assessed by Mandard grading (p<0.001).   There were no 
significant associations between R status and either the surgical approach (p=0.531) 
or the use of neoadjuvant chemotherapy (p=0.105).  
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Post-hoc pairwise analyses found that, where differences were detected across the 
resection margin groups, this was largely a result of variations between R1a and R0, 
rather than between R1a and R1b. For example, the rates of peri-neural invasion 
were 42% in R1a and 49% in R1b, compared to 20% in R0.  The only instance in which 
significant differences between R1a and R1b were observed was for tumour type 
(p=0.027), where R1b patients were less likely to have squamous cell carcinoma 
(SCC) than those in the R1a group (11% vs. 28%). 
 
Survival analysis found both overall (p=0.001, Figure 2a) and recurrence-free 
(p<0.001, Figure 2b) survival to differ significantly across the three CRM categories. 
Median overall survival was found to be similar for the R0 and R1a groups (25 vs. 27 
months, p=0.334), but to be significantly shorter in the R1b group (15 months, 
p=0.037). A similar trend was observed for recurrence-free survival (Table 2). 
 
Survival analyses: College of American Pathologists vs. Royal College of 
Pathologists guidelines 
 
CRM was then reclassified based on the two guidelines, with Royal College of 
Pathologists treating the R1a group as having involved CRM (R1), whilst College of 
American Pathologists treated these patients as being non-involved (R0). As a result, 
according to the Royal College of Pathologists guidelines, 34% of the cohort had an 
involved CRM whereas, according to College of American Pathologists guidelines, 
only 16% had an involved CRM. Univariable survival analyses using these guidelines 
found that patients in the R1 groups of both the College of American Pathologists 
and Royal College of Pathologists guidelines had significantly shorter survival than R0 
patients. However, the difference between the groups was marginally larger for 
College of American Pathologists than for Royal College of Pathologists (HR: 1.80 vs. 
1.48, Figure 2c and 2d). The same trend was observed for recurrence-free survival 
(HR: 1.92 vs.  1.62). 
 
Subgroup analyses 
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This analysis was then repeated within selected patient subgroups (Table 3). This 
found that the greatest difference in survival between R1 and R0 patients was in 
those where chemotherapy was not used (N=91), with HRs of 2.32 (p=0.012) and 
2.02 (p=0.022) for R1 vs. R0 in the College of American Pathologists and Royal 
College of Pathologists guidelines, respectively. Neither of the guidelines performed 
well for the subgroup of patients with N0 stage (n=153), with HRs of 1.39 (p=0.417) 
for College of American Pathologists and 0.94 (p=0.843) for Royal College of 
Pathologists. Similar findings were observed for the subgroup of T3 stage patients 
(N=260), with HRs for 1.38 (p=0.097) for College of American Pathologists and 1.10 
(p=0.545) for Royal College of Pathologists. Consistent results were observed for 
recurrence-free survival. 
 
Multivariable analyses 
 
Multivariable analyses were then performed, to consider the effect of CRM after 
accounting for potentially confounding factors. This analysis found overall patient 
survival to be significantly shorter with increasing N-stage, lymphovascular invasion, 
and in those that did not receive neoadjuvant chemotherapy (Table 4 and Figure 3a-
c). A significant association with age was also detected, with survival found to be 
longest in the most elderly group (Figure 3d). After accounting for these factors, no 
significant difference in patient survival was detected between patients with CRM of 
R1 vs. R0 by either the College of American Pathologists (HR: 1.21, 95% CI: 0.81 – 
1.81, p=0.353) or Royal College of Pathologists (HR: 1.02, 95% CI: 0.73 – 1.44, 
p=0.907) guidelines. Multivariable analysis of recurrence-free survival returned 
similar results (Table 4).  
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Discussion: 
 
These results demonstrate that CRM involvement is significantly associated with 
higher T and N staging, poor tumour differentiation, presence of perineural and 
lymphovascular invasion and longer tumour length.   There are also differences in 
patient demographics, disease and treatment factors between patients dependant 
on CRM status: predominantly in R0 vs. R1a, but less so between R1a vs. R1b. 
Despite this, univariable analysis found survival to be similar in R0 vs. R1a, but 
significantly worse in R1b vs. R1a. As a result, the College of American Pathologists 
guideline is more strongly associated with survival in univariable analysis, as this 
combines the groups with the most similar outcomes together (i.e.R0 and R1a). 
Multivariable analysis found that, after accounting for other confounding factors 
such as lymphovascular invasion and N-stage, neither of the CRM classifications were 
independent predictors of either overall or recurrence-free survival. 
 
We were unable to demonstrate the prognostic significance of CRM involvement 
using multivariable analysis, which has been shown in historical studies(8,10–14,23). 
Heterogeneity exists between these studies and our report because of differing 
methodologies and variability in confounding factors, which include study population 
size, length of follow-up, methodology (retrospective or prospective in nature), the 
proportion receiving neoadjuvant chemotherapy and operative techniques 
employed. Interestingly, studies with the largest datasets (314 and 329 patients) and 
longest duration of follow-up with also concluded that CRM was not associated with 
prognosis on multivariable analysis (20).  Nevertheless, despite their larger datasets, 
neither of these studies included patients with preoperative chemotherapy. 
Likewise, a ten year follow-up study by Theologou et al (32) (n=199), who restaged 
patients according the 7
th
 edition TNM and who received neoadjuvant 
chemotherapy, showed no prognostic significance on multivariable analysis. We 
therefore demonstrate CRM to be a non-significant prognostic marker on 
multivariable analysis in the largest prospectively-collected dataset, the majority of 
whom received neoadjuvant chemotherapy and who were staged with the 7
th
 
edition TNM. This suggests that CRM involvement should not be considered as a 
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major prognostic marker in patients who undergo oesophagectomy. As it is not a 
significant independent predictor of outcome, there could be an argument to avoid 
the routine reporting the CRM status. However, it is recommended that it continue 
to be assessed to help in quality assurance and surgical audit, provided the treating 
teams understand it does not appear to be a strong prognostic factor. 
 
Furthermore, superiority between Royal College of Pathologists or College of 
American Pathologists definitions has not yet been established and has been 
explored to a limited degree in the existing literature with conflicting results. Of the 
two systematic reviews performed in patients with oesophageal cancer(33–35) and 
the one systematic review performed specifically in patients with squamous cell 
carcinoma (36), results were mixed. Wu et al.(33) suggested superiority of the 
College of American Pathologists definition whereas Chan et al.(34) and Ahmad et 
al.(35) suggested superiority of the Royal College of Pathologists criteria. On 
consideration of the individual studies, those that designated Royal College of 
Pathologists as superior tended to have retrospective follow-up, small-medium sized 
cohort (n=98-226) and patients who received neoadjuvant chemotherapy(20–22) 
whereas those in support of College of American Pathologists excluded patients who 
received neoadjuvant chemotherapy(23,24). We report neither Royal College of 
Pathologists nor College of American Pathologists to be discriminative as their 
predictive accuracy for survival outcomes was low in both classification systems. This 
finding is supported other studies (25)(26), although our study population is more 
generalizable and representative than these previous studies.  
 
We chose to include all T stages in our overall analysis to increase the generalizability 
of our work. Some studies have limited their analysis to T3 tumours only. The 
rationale for this is that CRM involvement should not occur in T1/T2 disease unless 
the surgical field is violated. Patients with T4 tumours are less likely to have clear 
CRM; however, as a lot of these are due to direct invasion of the diaphragmatic 
crura, it is possible to achieve R0 clearance with wide diaphragmatic margins.  
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Lymph node involvement is a well-established marker of prognosis in oesophageal 
cancer(37), but the importance of CRM involvement in relation to N stage is 
disputed. Griffiths et al.(8) showed that CRM was a more significant prognostic 
marker if patients had a low lymph node burden, suggesting lymph node status was 
a more important factor in long-term survival(38). Yet, Saha et al.(10) found that 
both CRM involvement and lymph node involvement were independent prognostic 
factors. In addition, they reported that survival of node negative patients could be 
compromised with CRM involvement. We have failed to confirm this on our 
subgroup analysis. Our study shows that N stage categorisation of the 7
th
 edition of 
the TNM offers a superior prognostic marker compared to CRM involvement. Our 
multivariable analyses also revealed the independent prognostic importance of 
lymphovascular invasion. This is in accordance with other studies which have  
reported the prognostic significance of lymphovascular(4,15,39) and perineural 
invasion(4) on multivariable analyses.  
 
The chemotherapy regimens implemented in our study were typically MAGIC(27) 
and OE02(28). The MAGIC(27) trial did not compare outcomes by CRM status, 
however did report a significant decrease in median oesophageal diameter in the 
neoadjuvant chemotherapy treated group. The OE02 trial(28) reported increased 
incidence of unresectable tumours and macroscopically incomplete resections in the 
surgery only group. Neither trial specifically assessed the effect of CRM. The fact that 
neoadjuvant chemotherapy use was an independent predictor of survival in our 
study underpins its value in the modern management of oesophageal cancer.    
 
There has been recent interest in assessing chemoradiotherapy as neoadjuvant 
therapy prior to oesophagectomy and some studies have shown a survival advantage 
from this treatment (40,41).  Intuitively, this could be related to sterilisation of the 
CRM.    To back up this hypothesis, in Chan et al’s meta-analysis of rates of CRM 
involvement in six studies of patients with neoadjuvant chemotherapy and four 
studies with neoadjuvant chemoradiotherapy, reduced rates of CRM involvement 
were found in those treated with chemoradiotherapy (42).   In the group treated 
with neoadjuvant chemotherapy, the rate of CRM involvement was 15.8% (72 of 
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457) and 34.3% (361 of 1053) according to College of American Pathologists and 
Royal College of Pathologists criteria, respectively.   However, in patients treated 
with neoadjuvant chemoradiotherapy, CRM involvement was 11.2% (50 of 446) and 
31.9% (259 of 812) according to College of American Pathologists and Royal College 
of Pathologists criteria, respectively.  In the CROSS randomised trial, overall R0 
resection margins were achieved in 92% of patients in the chemoradiotherapy group 
compared with only 69% in the surgery group (P<0.001).  This was largely due to 
rates of complete pathological response rates of 29% in the chemoradiotherapy 
group where a significant survival advantage was observed (40).  As no specific 
information was given regarding the CRM status in the CROSS study it difficult to 
interpret in light of our results.  It is likely that proximal and distal margin 
involvement overrides the prognostic implications of CRM involvement and that is 
why we excluded these patients from our study.    
 
The impact of surgical approach on CRM involvement has been assessed in some 
other studies. One study compared Minimally Invasive Oesophagectomy, 
Conventional Open and Hybrid oesophgectomy and showed that neither CRM 
involvement nor survival differed with surgical procedure(43). Another 
demonstrated significant differences in CRM involvement between open and 
laparascopic transhiatal oesophagectomies(12). A Scottish audit(44) reported 
increased CRM involvement in transhiatal oesophagectomy compared to the Ivor 
Lewis procedure, although the radicality of resection in this paper has been 
questioned. In addition, Haverkamp et al. identified increased CRM involvement in 
patients treated with extended total gastrectomy as opposed to oesophagectomy 
for junctional adenocarcinoma(45). 
 
Our study has a range of strengths and limitations.   Although it was retrospective, it 
was largely an analysis of high quality prospectively collected data from a specialist 
high volume unit.   Inherent with other similar studies in this area it suffers from 
heterogeneous features, such as the changes in type of neoadjuvant chemotherapy 
used, operative procedures performed and the consultant surgical team.   However, 
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CRM status did not appear to be related to type of oesophagectomy or the use of 
neoadjuvant chemotherapy.  We also acknowledge some missing data, including 
rates of perineural and lymphovascular invasion, as these have recently been shown 
to be relevant.  
 
In conclusion, analysis of our large cohort did not find CRM involvement to be an 
independent prognostic marker of patient survival. Rates of CRM involvement were 
not found to differ significantly with the surgical procedure performed and, 
importantly, Minimally Invasive Oesophagectomy did not appear to compromise the 
CRM. Lymph node involvement and lymphovascular invasion provide superior 
prognostic information in patients with oesophageal cancer. Neither the College of 
American Pathologists nor the Royal College of Pathologists definitions of 
involvement were found to be significantly discriminatory after accounting for these 
factors.  
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Tables legends 
 
Table 1a – Comparison of demographics and tumour factors between resection 
margin groups 
Bold p-values are significant at p<0.05 
Key: 
aData reported as mean±SD, with overall p-value from one-way ANOVA, and pairwise 
comparisons from Dunnett's  tests. 
bData reported as N (%), with overall p-value from Fisher's exact test, and pairwise 
comparisons from Bonferroni-corrected Fisher's exact tests. 
cData reported as N (%), with overall p-value from Chi-square tests. 
dData reported as N (%), with overall p-value from Kruskal-Wallis tests (treating the 
factor as ordinal), and pairwise comparisons from Dunn's tests. 
eData reported as median (IQR), with overall p-value from Kruskal-Wallis tests, and 
pairwise comparisons from Dunn's tests. 
Adeno  –  Adenocarcinoma 
SCC  - Squamous Cell Carcinoma 
GOJ - Gastro-oesophageal junction  (Siewert type) 
v7 - 7th Edition TNM 
 
Table 1b – Comparison of tumour and treatment factors between resection margin 
groups 
*In patients that received chemotherapy 
Bold p-values are significant at p<0.05 
Key: 
aData reported as mean±SD, with overall p-value from one-way ANOVA, and pairwise 
comparisons from Dunnett's tests. 
bData reported as N (%), with overall p-value from Fisher's exact test, and pairwise 
comparisons from Bonferroni-corrected Fisher's exact tests. 
cData reported as N (%), with overall p-value from Chi-square tests. 
dData reported as N (%), with overall p-value from Kruskal-Wallis tests (treating the 
factor as ordinal), and pairwise comparisons from Dunn's tests. 
eData reported as median (IQR), with overall p-value from Kruskal-Wallis tests, and 
pairwise comparisons from Dunn's tests. 
 
Hybrid - laparoscopic gastric mobilisation and open right  
thoracotomy 
MIO  - Fully Minimally Invasive Oesophagectomy 
 
Table 2 – Univariable survival analysis by resection margin for the whole 
cohort 
Hazard ratios and p-values are from univariable Cox regression models, and 
median survival times are Kaplan-Meier estimates 
Bold p-values are significant at p<0.05. 
 
CAP  -  College of American Pathologists definition with CRM 
involvement defined as at the margin only(22) 
RCPath - Royal College of Pathologists definition with CRM 
involvement defined as within 1mm of the margin(23)  
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Table 3 – Subgroup analyses 
Hazard ratios and p-values are from univariable Cox regression models, and are for R1, 
relative to R0. 
Bold p-values are significant at p<0.05 
 
 
CAP  -  College of American Pathologists definition with CRM 
involvement defined as at the margin only(22) 
RCPath  - Royal College of Pathologists definition with CRM involvement  
defined as within 1mm of the margin(23) 
 
Table 4 – Multivariable analysis of overall survival and recurrence free 
survival 
Results are from multivariable Cox regression models. All factors in Table 1a/b 
were initially considered for inclusion in backwards stepwise models to identify 
significant independent predictors of outcome. Significant factors were then 
included in models alongside the resection margin. The final models are based on 
N=256, after excluding cases with missing data. 
Bold p-values are significant at p<0.05 
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Figure Legends 
 
Figure 1 
 
Microscopy images of various CRM status in lower oesophageal adenocarinoma.    
An R0 margin is shown with > 1mm distance from the tumour and the inked CRM 
(Figure 1a).   Tumour within 1mm of the inked CRM (R1a) (Figure 1b).   Tumour 
directly involving the inked CRM (R1b) (Figure 1c) 
 
Figure 2 
 
Kaplan-Meier survival curves for CRM.   Overall survival (Figure 2a) and recurrence 
free survival (Figure 2b) for resection margin status (R0, R1a, R1b), with p-values 
representing comparisons across the three groups.    
Overall survival by the American College of Pathologists (CAP) definition of CRM 
status (Figure 2c) and by the Royal College of Pathologists definition of CRM status 
(Figure 2d) 
 
Figure 3 
 
Kaplan-Meier survival curves for overall survival in N Stage (Figure 3a), 
Lymphovascular Invasion (Figure 3b), Neoadjuvant Chemotherapy (Figure 3c) and 
patient age (Figure 3d). 
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Table 1a – Comparison of demographics and tumour factors between resection margin groups 
  
Resection Margin p-Values 
 
N 
R0 
(N=257) 
R1a 
(N=71) 
R1b 
(N=62) Overall 
R1a  
vs. R0 
R1a 
 vs. R1b 
Age (Years) 
a
 390 67.0±9.5 68.3±9.1 67.4±7.9 0.594 - - 
Gender
 b
 390 
   
0.611 - - 
Male 
 
201 (78%) 55 (77%) 52 (84%) 
   Female 
 
56 (22%) 16 (23%) 10 (16%) 
   Tumour Type 
b
 390 
   
0.040 0.053 0.027 
Adeno 
 
207 (81%) 47 (66%) 54 (87%) 
   SCC 
 
43 (17%) 20 (28%) 7 (11%) 
   Other 
 
7 (3%) 4 (6%) 1 (2%) 
   Site of Lesion
 c
 385 
   
0.185 - - 
Upper  0 (0%) 1 (1%) 1 (2%)    
Mid  17 (7%) 8 (11%) 3 (5%)    
Lower/GOJ1  180 (71%) 55 (77%) 48 (77%)    
GOJ2 
 
45 (18%) 6 (8%) 9 (15%) 
   
GOJ3 
  
10 (4%) 
 
1 (1%) 
 
1 (2%) 
    
Differentiation
 d
 387 
   
<0.001 <0.001 0.904 
Poor 
 
79 (31%) 37 (53%) 39 (64%) 
   Mod 
 
142 (55%) 32 (46%) 18 (30%) 
   Well 
 
35 (14%) 1 (1%) 4 (7%) 
   T-Stage
 d
 390 
   
<0.001 <0.001 0.334 
T0 
 
15 (6%) 0 (0%) 0 (0%) 
   T1 
 
56 (22%) 0 (0%) 0 (0%) 
   T2 
 
42 (16%) 0 (0%) 0 (0%) 
   T3 
 
139 (54%) 70 (99%) 51 (82%) 
   T4 
 
5 (2%) 1 (1%) 11 (18%) 
   N-Stage (v7)
 d
 390 
   
<0.001 <0.001 0.377 
N0 
 
128 (50%) 13 (18%) 12 (19%) 
   N1 
 
68 (26%) 27 (38%) 12 (19%) 
   N2 
 
38 (15%) 17 (24%) 16 (26%) 
   N3 
 
23 (9%) 14 (20%) 22 (35%) 
   Bold p-values are significant at p<0.05 
Key: 
a
Data reported as mean±SD, with overall p-value from one-way ANOVA, and pairwise comparisons 
from Dunnett's  tests. 
b
Data reported as N (%), with overall p-value from Fisher's exact test, and pairwise comparisons from 
Bonferroni-corrected Fisher's exact tests. 
c
Data reported as N (%), with overall p-value from Chi-square tests. 
d
Data reported as N (%), with overall p-value from Kruskal-Wallis tests (treating the factor as ordinal), 
and pairwise comparisons from Dunn's tests. 
e
Data reported as median (IQR), with overall p-value from Kruskal-Wallis tests, and pairwise 
comparisons from Dunn's tests. 
Adeno  –  Adenocarcinoma 
SCC  - Squamous Cell Carcinoma 
GOJ - Gastro-oesophageal junction  (Siewert type) 
v7 - 7
th
 Edition TNM 
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Table 1b – Comparison of tumour and treatment factors between resection margin groups 
 
Resection Margin p-Values 
N 
R0 
(N=257) 
R1a 
(N=71) 
R1b 
(N=62) Overall 
R1a 
vs. R0 
R1a 
vs. R1b 
Peri-Neural Invasion 
b
 302 <0.001 0.002 1.000 
No 
 
154 (80%) 34 (58%) 26 (51%) 
Yes 
 
38 (20%) 25 (42%) 25 (49%) 
Lymphovascular Invasion 
b
 257 <0.001 <0.001 1.000 
No 
 
116 (68%) 13 (30%) 14 (32%) 
Yes 
 
54 (32%) 30 (70%) 30 (68%) 
Lymph nodes – Total 
a
 390 29.4±11.7 33.8±11.4 29.6±11.6 0.016 0.009 0.065 
Lymph nodes - Involved
 e
 390 1 (0 - 2) 2 (1 - 5) 4 (1 - 9) <0.001 <0.001 0.277 
Lymph nodes - Ratio
 e
 390 0.02 (0.00 - 0.09) 0.06 (0.02 - 0.17) 0.13 (0.05 - 0.32) <0.001 <0.001 0.333 
Tumour Length
 e
 359 30 (20 - 45) 37 (25 - 50) 40 (29 - 50) 0.014 0.044 1.000 
Operation Type 
b
 390 0.531 - - 
Hybrid 106 (41%) 35 (49%) 23 (37%) 
MIO 
 
57 (22%) 14 (20%) 15 (24%) 
Open 
 
58 (23%) 16 (23%) 19 (31%) 
Other 
 
36 (14%) 6 (8%) 5 (8%) 
Neoadjuvant Chemotherapy
 b
 389 0.105 - - 
No 
 
61 (24%) 11 (15%) 19 (31%) 
Yes 
 
196 (76%) 60 (85%) 42 (69%) 
Chemo Cycles Planned
 e
 * 286 3 (2 - 3) 2 (2 - 3) 3 (2 - 3) 0.317 - - 
Chemo Cycles Received
 e
 * 273 2 (2 - 3) 2 (2 - 3) 3 (2 - 3) 0.278 - - 
Mandard Score
 d
 * 251 <0.001 <0.001 1.000 
Mandard 1 (Complete) 
 
16 (10%) 0 (0%) 0 (0%) 
Mandard 2 
 
25 (15%) 0 (0%) 2 (6%) 
Mandard 3 
 
34 (21%) 9 (18%) 8 (23%) 
Mandard 4 
 
57 (35%) 21 (41%) 10 (29%) 
Mandard 5 (None) 
 
33 (20%) 21 (41%) 15 (43%) 
*In patients that received chemotherapy 
Bold p-values are significant at p<0.05 
Key: 
a
Data reported as mean±SD, with overall p-value from one-way ANOVA, and pairwise 
comparisons from Dunnett's tests. 
b
Data reported as N (%), with overall p-value from Fisher's exact test, and pairwise 
comparisons from Bonferroni-corrected Fisher's exact tests. 
c
Data reported as N (%), with overall p-value from Chi-square tests. 
d
Data reported as N (%), with overall p-value from Kruskal-Wallis tests (treating the factor as 
ordinal), and pairwise comparisons from Dunn's tests. 
e
Data reported as median (IQR), with overall p-value from Kruskal-Wallis tests, and pairwise 
comparisons from Dunn's tests. 
 
Hybrid - laparoscopic gastric mobilisation and open right  
thoracotomy 
MIO  - Fully Minimally Invasive Oesophagectomy 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
2 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
1 
 
Table 2 – Univariable survival analysis by resection margin for the whole cohort 
  Overall Survival Recurrence-Free Survival 
Resection Margin HR (95% CI) Median (95% CI) p-Value HR (95% CI) Median (95% CI) p-Value 
Three Categories   0.001   <0.001 
R0 0.84 (0.59 - 1.20) 25.1 (17.3 - 32.9) 0.334 0.76 (0.55 - 1.05) 21.5 (16.9 - 26.0) 0.095 
R1a - 27.0 (10.2 - 43.8) - - 16.5 (11.9 - 21.1) - 
R1b 1.57 (1.03 - 2.40) 14.9 (10.9 - 18.8) 0.037 1.56 (1.06 - 2.30) 11.2 (8.7 - 13.6) 0.026 
CAP Guidelines   <0.001   <0.001 
R0 - 26.3 (19.4 - 33.3) - - 20.1 (16.5 - 23.6) - 
R1 1.80 (1.30 - 2.50) 14.9 (10.9 - 18.8) <0.001 1.92 (1.42 - 2.61) 11.2 (8.7 - 13.6) <0.001 
RCPath Guidelines   0.006   <0.001 
R0 - 25.1 (17.3 - 32.9) - - 21.5 (16.9 - 26.0) - 
R1 1.48 (1.12 - 1.95) 18.0 (10.1 - 25.8) 0.006 1.62 (1.25 - 2.10) 13.6 (10.8 - 16.4) <0.001 
Hazard ratios and p-values are from univariable Cox regression models, and median survival times are Kaplan-Meier estimates 
Bold p-values are significant at p<0.05. 
 
CAP  -  College of American Pathologists definition with CRM involvement defined as at the margin only(22) 
RCPath - Royal College of Pathologists definition with CRM involvement defined as within 1mm of the margin(23)
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Table 3 – Subgroup analyses 
Resection  
Margin 
Overall Survival Recurrence-Free Survival 
HR (95% CI) p-Value HR (95% CI) p-Value 
 
Chemotherapy Not Used (N=91) 
CAP (R1) 2.32 (1.21 - 4.46) 0.012 2.37 (1.31 - 4.31) 0.005 
RCPath (R1) 2.02 (1.11 - 3.70) 0.022 2.05 (1.18 - 3.57) 0.011 
 
Chemotherapy Used (N=298) 
CAP (R1) 1.64 (1.11 - 2.43) 0.013 1.76 (1.22 - 2.54) 0.003 
RCPath (R1) 1.35 (0.99 - 1.85) 0.060 1.50 (1.12 - 2.00) 0.007 
 
T-Stage 3 (N=260) 
CAP (R1) 1.38 (0.94 - 2.00) 0.097 1.41 (1.00 - 2.00) 0.051 
RCPath (R1) 1.10 (0.80 - 1.52) 0.545 1.14 (0.85 - 1.54) 0.379 
 
N-Stage 0 (N=153) 
CAP (R1) 1.39 (0.63 - 3.08) 0.417 1.79 (0.88 - 3.63) 0.110 
RCPath (R1) 0.94 (0.50 - 1.77) 0.843 1.05 (0.58 - 1.89) 0.883 
 
N-Stage 1-3  (N=237) 
CAP (R1) 1.74 (1.20 - 2.51) 0.003 1.70 (1.01 - 2.40) 0.002 
RCPath (R1) 1.52 (1.10 - 2.10) 0.012 1.58 (0.17 - 2.13) 0.003 
Hazard ratios and p-values are from univariable Cox regression models, and are for R1, relative to R0. 
Bold p-values are significant at p<0.05 
 
 
CAP  -  College of American Pathologists definition with CRM 
involvement defined as at the margin only(22) 
RCPath  - Royal College of Pathologists definition with CRM involvement  
defined as within 1mm of the margin(23) 
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Table 4 – Multivariable analysis of overall survival and recurrence free survival 
   CAP RCPath 
   HR (95% CI) p-Value HR (95% CI) p-Value 
Overall 
Survival 
Resection 
Margin (R1) 1.21 (0.81 - 1.81) 
0.352 
1.02 (0.73 - 1.44) 
0.907 
Age (Years)   0.039   0.030 
<60  - - -  - 
60-64 0.69 (0.41 - 1.16) 0.161 0.67 (0.40 - 1.13) 0.135 
65-69 0.92 (0.58 - 1.47) 0.742 0.93 (0.58 - 1.49) 0.761 
70-74 1.00 (0.61 - 1.64) 0.989 1.00 (0.61 - 1.63) 0.988 
75+ 0.48 (0.28 - 0.82) 0.007 0.47 (0.28 - 0.81) 0.006 
N-Stage   0.004   0.002 
N0  - -  - - 
N1 1.03 (0.66 - 1.63) 0.889 1.02 (0.65 - 1.62) 0.921 
N2 1.65 (1.00 - 2.71) 0.049 1.65 (1.00 - 2.72) 0.051 
N3 2.17 (1.32 - 3.58) 0.002 2.23 (1.35 - 3.68) 0.002 
Lymphovascular 
Invasion 2.70 (1.85 - 3.93) 
<0.001 
2.74 (1.86 - 4.04) 
<0.001 
Neoadjuvant 
Chemo. 0.65 (0.43 - 0.97) 
0.035 
0.64 (0.43 - 0.95) 
0.029 
       
Recurrence 
Free 
Survival 
Resection 
Margin (R1) 1.37 (0.93 - 2.02) 
0.107 
0.99 (0.71 - 1.37) 
0.936 
Age (Years)   0.027   0.019 
<60  - - -  - 
60-64 0.71 (0.43 - 1.18) 0.183 0.68 (0.41 - 1.12) 0.131 
65-69 0.94 (0.60 - 1.47) 0.774 0.94 (0.60 - 1.48) 0.804 
70-74 1.05 (0.65 - 1.69) 0.837 1.02 (0.63 - 1.64) 0.946 
75+ 0.49 (0.30 - 0.82) 0.006 0.48 (0.29 - 0.80) 0.005 
N-Stage   0.005   0.002 
N0  - - -  - 
N1 1.03 (0.67 - 1.59) 0.893 1.03 (0.66 - 1.59) 0.906 
N2 1.54 (0.96 - 2.48) 0.076 1.56 (0.96 - 2.53) 0.074 
N3 2.11 (1.31 - 3.40) 0.002 2.23 (1.38 - 3.62) 0.001 
Lymphovascular 
Invasion 2.83 (1.97 - 4.05) 
<0.001 
2.91 (2.00 - 4.22) 
<0.001 
Neoadjuvant 
Chemo. 0.73 (0.50 - 1.08) 
0.114 
0.71 (0.48 - 1.04) 
0.075 
Results are from multivariable Cox regression models. All factors in Table 1a/b were initially 
considered for inclusion in backwards stepwise models to identify significant independent 
predictors of outcome. Significant factors were then included in models alongside the 
resection margin. The final models are based on N=256, after excluding cases with missing 
data. 
Bold p-values are significant at p<0.05 
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